Your browser doesn't support javascript.
loading
Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Joshi, Shweta; Liu, Kevin X; Zulcic, Muamera; Singh, Alok R; Skola, Dylan; Glass, Christopher K; Sanders, P Dominick; Sharabi, Andrew B; Pham, Timothy V; Tamayo, Pablo; Shiang, Daniel; Dinh, Huy Q; Hedrick, Catherine C; Morales, Guillermo A; Garlich, Joseph R; Durden, Donald L.
Afiliação
  • Joshi S; UCSD Department of Pediatrics, University of California, San Diego, San Diego, California. shjoshi@ucsd.edu durden@signalrx.com.
  • Liu KX; UCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
  • Zulcic M; UCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
  • Singh AR; UCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
  • Skola D; UCSD School of Medicine, University of California, San Diego, San Diego, California.
  • Glass CK; UCSD School of Medicine, University of California, San Diego, San Diego, California.
  • Sanders PD; Moores Cancer Center, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, San Diego, California.
  • Sharabi AB; Moores Cancer Center, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, San Diego, California.
  • Pham TV; UCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
  • Tamayo P; Office of Cancer Genomics, University of California, San Diego, San Diego, California.
  • Shiang D; Office of Cancer Genomics, University of California, San Diego, San Diego, California.
  • Dinh HQ; UCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
  • Hedrick CC; La Jolla Institute of Allergy and Immunology, La Jolla, California.
  • Morales GA; La Jolla Institute of Allergy and Immunology, La Jolla, California.
  • Garlich JR; SignalRx Pharmaceuticals, Omaha, Nebraska.
  • Durden DL; SignalRx Pharmaceuticals, Omaha, Nebraska.
Mol Cancer Ther ; 19(3): 755-764, 2020 03.
Article em En | MEDLINE | ID: mdl-31974273
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Neoplasias do Colo / Carcinoma Pulmonar de Lewis / Classe Ib de Fosfatidilinositol 3-Quinase / Quinase Syk / Inibidores de Fosfoinositídeo-3 Quinase / Macrófagos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Neoplasias do Colo / Carcinoma Pulmonar de Lewis / Classe Ib de Fosfatidilinositol 3-Quinase / Quinase Syk / Inibidores de Fosfoinositídeo-3 Quinase / Macrófagos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article